Heart Health Hypertension, guidelines, therapies- use of ACE inhibitors, angiotensin receptor blockers (ARB), calcium channel blockers and diuretics with or without β-blockers, combination therapy, barriers​. e-Learning Hypertension, Dyslipidaemia and Cardiometabolic Disease VIEW INFOGRAPHIC Infographics Hypertension, Dyslipidaemia, and Cardiometabolic Disease – Insights on Pathophysiology, Interplay, and Therapeutic Management VIEW INFOGRAPHIC Videos [Mandarin Translation] Managing Hypertension in the Context of Cardiometabolic Disease WATCH VIDEO Managing Hypertension in the Context of Cardiometabolic Disease WATCH VIDEO Deciphering the Complexities of Cardiometabolic Diseases: Expert Perspectives on Hypertension and Dyslipidemia WATCH VIDEO Articles Cardiovascular Risk Factor and Disease Mortality Among Asian Indian, Chinese, and Filipino Adults in the United States, 2018 to 2023 READ MORE Association between cardiometabolic index and hypertension among US adults from NHANES 1999–2020 READ MORE An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists READ MORE South Asians and cardiometabolic health: A framework for comprehensive care for the individual, community, and population – An American society for preventive cardiology clinical practice statement READ MORE Primary Prevention of Cardiovascular Disease in Asia: Challenges: A Narrative Review READ MORE Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk READ MORE Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East READ MORE Reducing the global prevalence of cardiometabolic risk factors: a bet worth winning READ MORE Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk READ MORE Tackling cardiometabolic disease in southeast Asia: local research to inform local practice READ MORE Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model READ MORE Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial READ MORE The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions READ MORE The synergistic effect of obesity and dyslipidemia on hypertension: results from the STEPS survey READ MORE Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 READ MORE Management of Hypertension in the Asia-Pacific Region: A Structured Review READ MORE Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime READ MORE Asia-Pacific Investigators and Asian Enrollment in Cardiometabolic Trials: Insights From Publications Between 2011 and 2020 READ MORE Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia READ MORE The Prevalence and Risk Factors of Hypertension among the Urban Population in Southeast Asian Countries: A Systematic Review and Meta-Analysis READ MORE Dyslipidemia and Cardiometabolic Syndrome READ MORE The 2017 Focused Update of the Guidelines of theTaiwan Society of Cardiology (TSOC) and theTaiwan Hypertension Society (THS) for theManagement of Hypertension READ MORE How would you rate this content? Submit Rating
